Skip to content
value.today
Sunshine Biopharma, Inc logo

Sunshine Biopharma, Inc

Formerly Mountain West Business Solutions, Inc.

Sunshine Biopharma, Inc is listed today as Sunshine Biopharma, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Sunshine Biopharma, Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$5 MPrivate placement after listing$2 to $10 million

Sunshine Biopharma, Inc: Private sale, May 2023

Investors in this round

1 investor had bought by the notice of May 17, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$599,579
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Colorado

People named in the notice

  • Abderrazzak N. Merzouki · Executive Officer, Director · Chief Operating Officer
  • Camille N. Sebaaly · Executive Officer · Chief Financial Officer and Secretary
  • Steve N. Slilaty · Executive Officer, Director · Chairman, Chief Executive Officer, and President
  • Andrew N. Keller · Director
  • David N. Natan · Director
  • Rabi N. Kiderach · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Aegis Capital Corp. (CRD 15007) · New York, New YorkSold in NY

Signed by Dr. Steve N. Slilaty, Chairman, Chief Executive Officer, and President. Source: SEC Form D, newest notice filed May 17, 2023. Read the notice at the SEC.

equity, optionsSEC
Apr 2022$20 MPrivate placement after listing$10 to $50 million

Sunshine Biopharma, Inc: Private sale, Apr 2022

Investors in this round

9 investors had bought by the notice of Apr 29, 2022: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,340,001
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Colorado

People named in the notice

  • Abderrazzak N. Merzouki · Executive Officer, Director · Chief Operating Officer
  • Camille N. Sebaaly · Executive Officer · Chief Financial Officer and Secretary
  • Steve N. Slilaty · Executive Officer, Director · President, Chief Executive Officer and Chairman
  • Andrew N. Keller · Director
  • David N. Natan · Director
  • Rabi N. Kiderchah · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Aegis Capital Corp. (CRD 15007) · New York, New YorkSold in CT, NV, NY

Remarks in the notice

  • On fees: “Includes non accountable expense allowance of 2% of gross proceeds. Placement agent will also receive 5% fee for any warrant excercises.”

Signed by Steve N. Slilaty, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 29, 2022. Read the notice at the SEC.

equity, optionsSEC
Mar 2022$8 MPrivate placement after listing$2 to $10 million

Sunshine Biopharma, Inc: Private sale, Mar 2022

Investors in this round

9 investors had bought by the notice of Mar 18, 2022: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$960,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Colorado

People named in the notice

  • Abderrazzak N. Merzouki · Executive Officer, Director · Chief Operating Officer
  • Camille N. Sebaaly · Executive Officer · Chief Financial Officer and Secretary
  • Steve N. Slilaty · Executive Officer, Director · President, Chief Executive Officer and Chairman
  • Andrew N. Keller · Director
  • David N. Natan · Director
  • Rabi N. Kiderchah · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Aegis Capital Corp. (CRD 15007) · New York, New YorkSold in CT, NV, NY

Remarks in the notice

  • On fees: “Includes non-accountable expense allowance of 2% of gross proceeds.”

Signed by Steve N. Slilaty, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 18, 2022. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Sunshine Biopharma, Inc chose not to state its revenue in its newest notice of a funding round (May 2023).

    SEC Form D · May 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2023

That is all the official record says: Sunshine Biopharma, Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Sunshine Biopharma, Inc are on record.

Investors#

No investor of Sunshine Biopharma, Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Sunshine Biopharma, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sunshine Biopharma, Inc
NameRoleNamed in
Abderrazzak N. MerzoukiChief Operating OfficerMay 2023
Camille N. SebaalyChief Financial Officer and SecretaryMay 2023
Steve N. SlilatyChairman, Chief Executive Officer, and PresidentMay 2023
Abderrazzak N. MerzoukiChief Operating OfficerMay 2023
Andrew N. KellerDirectorMay 2023
David N. NatanDirectorMay 2023
Rabi N. KiderachDirectorMay 2023
Steve N. SlilatyChairman, Chief Executive Officer, and PresidentMay 2023
Rabi N. KiderchahDirectorApr 2022

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.